MAPK1 and sarcopenia: Consistently, muscle CSA measurements revealed that the newly formed myofibers of U0126-treated muscle had significantly larger diameters than those of carrier solution-treated aged TA muscle (Fig. 6D), supporting the potential of ERK inhibitors as new candidate therapeutic agents for sarcopenia.